This company has been marked as potentially delisted and may not be actively trading. NASDAQ:AVRO AVROBIO (AVRO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About AVROBIO Stock (NASDAQ:AVRO) 30 days 90 days 365 days Advanced Chart Get AVROBIO alerts:Sign Up Key Stats Today's Range N/A50-Day Range$1.40▼$18.2452-Week Range N/AVolume206,800 shsAverage Volume269,831 shsMarket Capitalization$62.85 millionP/E Ratio2.03Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Read More… Receive AVRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AVROBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address AVRO Stock News HeadlinesTECX Stock Hits 52-Week High, Soaring to $53.6 Amid Market OptimismJanuary 30, 2025 | msn.comOptimistic Outlook for Tectonic Therapeutic’s TX45: A Promising Candidate for Unmet Medical NeedsJanuary 28, 2025 | markets.businessinsider.comCan you still profit from AI this year? (Read this ASAP)AI isn’t dead — it’s just getting started. Weiss Ratings — ranked #1 by both the SEC and the Wall Street Journal — just issued 3 new “Buy” signals on under-the-radar AI stocks. See the names and ticker symbols now (for free).April 18, 2025 | Weiss Ratings (Ad)L'action TECX atteint un sommet sur 52 semaines à 53,41$December 25, 2024 | fr.investing.comL'action TECX atteint un sommet sur 52 semaines à 47,99$ dans un contexte de hausse des marchésNovember 13, 2024 | fr.investing.comPromising Potential and Strong Safety Profile Drive Buy Rating for Tectonic TherapeuticNovember 13, 2024 | markets.businessinsider.comTectonic Therapeutic: Promising Phase 1a Results and Strong Financial Health Justify Buy RatingNovember 11, 2024 | markets.businessinsider.comL'action TECX atteint un plus haut de 52 semaines à 38,14$ dans un contexte d'optimisme du marchéOctober 25, 2024 | fr.investing.comSee More Headlines AVRO Stock Analysis - Frequently Asked Questions How were AVROBIO's earnings last quarter? AVROBIO, Inc. (NASDAQ:AVRO) released its quarterly earnings results on Thursday, November, 4th. The company reported ($9.00) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($9.00). When did AVROBIO's stock split? AVROBIO shares reverse split before market open on Thursday, June 20th 2024. The 1-12 reverse split was announced on Thursday, June 20th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. When did AVROBIO IPO? AVROBIO (AVRO) raised $75 million in an IPO on Thursday, June 21st 2018. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities served as the underwriters for the IPO and Wedbush Securities was co-manager. What other stocks do shareholders of AVROBIO own? Based on aggregate information from My MarketBeat watchlists, some other companies that AVROBIO investors own include Meta Platforms (META), NVIDIA (NVDA), CymaBay Therapeutics (CBAY), Broadcom (AVGO), CrowdStrike (CRWD), Advanced Micro Devices (AMD) and Adobe (ADBE). Company Calendar Last Earnings11/04/2021Today4/18/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:AVRO CIK1681087 Webwww.avrobio.com Phone(617) 914-8420FaxN/AEmployees13Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.69 Trailing P/E Ratio2.03 Forward P/E RatioN/A P/E GrowthN/ANet Income$12.16 million Net MarginsN/A Pretax MarginN/A Return on Equity-50.52% Return on Assets-47.13% Debt Debt-to-Equity RatioN/A Current Ratio26.17 Quick Ratio26.17 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.13 per share Price / BookN/AMiscellaneous Outstanding Shares44,890,000Free Float40,764,000Market Cap$62.85 million OptionableOptionable Beta1.23 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free Report This page (NASDAQ:AVRO) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | Sponsored100-year-old investment secret predicts what?!A 100-year-old indicator has quietly predicted nearly every major market meltdown — including the Dot-Com Bust...Weiss Ratings | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AVROBIO, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AVROBIO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.